CARLSBAD, Calif., Feb. 11, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences:

• Oppenheimer 35^th Annual Healthcare Life Sciences Conference, February 11-12, 2025
  • Format: Fireside chat and one-on-one investor meetings
  • Presentation Date/Time: Wednesday, February 12, 2025, at 2:00 PM ET
  • Location: Virtual

• TD Cowen 45^th Annual Healthcare Conference, March 3-5, 2025
  • Format: Fireside chat and one-on-one investor meetings
  • Presentation Date/Time: Monday, March 3, 2025, at 9:50 AM ET
  • Location: Boston

• Jefferies Biotech on the Beach Summit, March 11-12, 2025
  • Format: One-on-one investor meetings
  • Location: Miami

• Barclays 27^th Annual Global Healthcare Conference, March 11-13, 2025
  • Format: Fireside chat and one-on-one investor meetings
  • Presentation Date/Time: Wednesday, March 12, 2025, at 8:30 AM ET
  • Location: Miami

A live and archived webcast of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website. 

About Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions. The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. TYRA-300 is expected to be evaluated in three Phase 2 studies: SURF302 for intermediate risk non-muscle invasive bladder cancer, BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial cancer. TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19⁺/FGFR4-driven cancers. TYRA is based in Carlsbad, CA. 

For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.

Contact:

Amy Conrad
This email address is being protected from spambots. You need JavaScript enabled to view it.